Vaxess Technologies Stock

Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.

Sign up today and learn more about Vaxess Technologies Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Vaxess Technologies Stock

Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.

Funding History

May 2012$70K
May 2013$3.8M
December 2013$1.0M
January 2015$225K
February 2015$1.0M
April 2015$220K
April 2015$150K
September 2016$1.4M
January 2017$863K
February 2017$6.0M
December 2017$1.5M
October 2018$650K
February 2019$3.6M
June 2019$8.2M
September 2020$256K
November 2022$27.0M
January 2023$10.0M


Co-Founder & CEO

Michael Schrader

Co-founder, VP of Research & Development

Kathryn Kosuda

Co-Founder, Senior VP of Strategy, BD and Operations

Livio Valenti

Member of SAB

George Siber

Board Director

Johannes Fruehauf

Board of Directors

Aaron Sandoski

Scientific Advisor

Thomas P. Monath


Peter Hutt


Eve Slater

Member of the Advisory Board

Vicki Sato


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: